Revive Therapeutics nears completion of nerve agent countermeasure study

Revive Therapeutics (RVVTF) announced an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure. This study is conducted in partnership with Defence R&D Canada – Suffield Research Centre, an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. After recent discussions with the DRDC, the research study on Bucillamine is now set to conclude by September 2025. With continued promising ongoing results and current DRDC and regulatory initiatives, there are potential pathways for Health Canada to grant faster approval for DRDC strategic stockpiling plans for treating nerve agent or organophosphate pesticide poisoning in 2026. In addition, plans are being pursued to explore the use of Bucillamine in traumatic brain injury from concussive/explosive forces and viral infections. In light of current world events, therapeutic options for the battlefield are becoming a high priority for nations involved. Bucillamine has the potential to become a vital option for medical countermeasures and in the battlefield.